会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明专利
    • BENZIMIDAZOLINYL PIPERIDINES AS CGRP LIGANDS
    • CA2345357A1
    • 2000-04-06
    • CA2345357
    • 1999-09-22
    • MERCK & CO INCMERCK SHARP & DOHME
    • HILL RAYMOND GEORGEPATCHETT ARTHUR AYANG LIHU
    • A61K31/4427A61K31/4433A61K31/454A61P3/10A61P9/10A61P25/04A61P25/06A61P29/00A61P35/00C07D401/04C07D409/14A61K31/415
    • A compound of formula I, wherein: R1 is naphthyl or benzothienyl which is unsubstituted or substituted at up to three substitutable positions independently by C1-6 alkyl, halogen, C1-6 alkoxy, CF3, OCF3, NO2, CN, methylenedioxy or ethylenedioxy; R2 is hydrogen, C1-8 alkyl, -(CH2)t-aryl wherein aryl is selected from phenyl, biphenyl and naphthyl, -(CH2)t- heteroaryl wherin heteroaryl is selected from tetrazolyl, oxadiazolyl, thiadiazolyl, triazolyl and pyrazinyl, -(CH2)qC(O)OR6, -(CH2)qOR6, - (CH2)qOC(O)R6, -(CH2)qC(O)R6, -(CH2)qC(O)(CH2)taryl, -(CH2)qN(R6)C(O)R6, - (CH2)qC(O)N(R6)2, -(CH2)qN(R6)SO2R6, -(CH2)qN(R6)C(O)N(R6)2, - (CH2)qOC(O)N(R6)2, -(CH2)qN(R6)C(O)OR6, -(CH2)qN(R6)SO2N(R6)2 and - (CH2)qS(O)mR6; R3 is NH2; R4 is hydrogen, C1-6 alkyl, C1-6 alkoxy, halogen, OCF3 or CF3; R5 is hydrogen, C1-6 alkyl, C1-6 alkoxy, halogen, OCF3 or CF3; R6 is hydrogen, C1-8 alkyl or C3-7 cycloalkyl, and when two R6 groups are prese nt and both represent C1-8 alkyl they may optionally together with the atom to which they are both attached form a C3-8 ring; Q is -(CH2)x-C(R7)(R7a)-(CH2) y- or -(CH2)x-V-(CH2)y-; R7 and R7a are independently chosen from hydrogen, CF3 , halogen, C1-6 alkyl and C1-6 alkoxy; V is a C3-8 non-aromatic cyclic or bicyclic ring or an aromatic ring which is benzene or naphthalene, said ring being unsubstituted or substituted at up to three substitutable positions independently by C1-6 alkyl, C1-6 alkoxy, halogen, OCF3, CF3, CN, NO2, methylenedioxy or ethylenedioxy; m is 0, 1 or 2; q is 0, 1, 2, 3 or 4; t is 0, 1, 2 or 3; x and y are independently 0, 1, 2, 3 or 4; or a pharmaceutically acceptable salt thereof; useful as CGRP (calcitonin gene-related peptide) receptor ligands, processes for their preparation, their use in therapy, pharmaceutical compositions comprising them and methods of treatment using them.